Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term RANDOMIZED-TRIAL. Found 23 abstracts

no pagination
Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian journal of andrology. 2014 May;16(3):372-7.   PMCID: PMC4023362
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs timeto neurologic progression in non-small-cell lung cancer patients with brain metases: results of a phase III trial. International Journal of Radiation Oncology Biology Physics. 2009 Mar;73(4):1069-76.   PMCID: not NIH funded
Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB, Yu M, Caterini J, Kim-Schulze S, DeBenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clinical Cancer Research. 2008 Aug;14(15):4843-9.
Suh WW, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Cosman BC, Saltz L, Johnstone PA. ACR appropriateness criteria on resectable rectal cancer. International Journal of Radiation Oncology Biology Physics. 2008 Apr;70(5):1427-30.
Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):477-84.
Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Seminars in Oncology. 2007 Apr;34(2):S1-S15.
Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: A retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clinical lung cancer. 2007 Mar;8(5):319-26.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology. 2007 Apr;25(12):1539-44.
Jordan VC. Opinion - Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer. 2007 Jan;7(1):46-53.
Jordan VC. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe Und Frauenheilkunde. 2007 May;67(5):443-50.
Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007 Jan;72(1):7-25.
Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. Journal of Urology. 2007 Nov;178(5):1883-7.
Opatt D, Morrow M, Hawley S, Schwartz K, Janz NK, Katz SJ. Conflicts in decision-making for breast cancer surgery. Annals of Surgical Oncology. 2007 Sep;14(9):2463-9.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 2007 Feb;30(2):509-20.
Punglia RS, Morrow M, Winer EP, Harris JR. Current concepts: Local therapy and survival in breast cancer. New England Journal of Medicine. 2007 Jun;356(23):2399-405.
Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3):277S-289S.
Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CG, Cordera F, Shupp HA, Li TY, Jordan VC. Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. Journal of Steroid Biochemistry and Molecular Biology. 2006 Dec;102(1-5):128-38.
Freedman GM, Anderson P, Li TY, Ross E, Swaby R, Goldstein L. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer. 2006 Dec;107(11):2552-8.
Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer - Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. European Journal of Cancer. 2006 Nov;42(17):2909-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term RANDOMIZED-TRIAL

RANDOMIZED-TRIAL breast cancer POSTMENOPAUSAL WOMEN THERAPY SURGICAL ADJUVANT BREAST CLINICAL-TRIALS BOWEL PROJECT P-1 ADJUVANT CHEMOTHERAPY SURVIVAL RADIATION-THERAPY ENDOTHELIAL GROWTH-FACTOR chemotherapy CARCINOMA ATHYMIC MICE ANTIESTROGENS PHASE-II TRIAL IRINOTECAN ADJUVANT TREATMENT CANCER DOUBLE-BLIND PHASE-III TRIAL tamoxifen ADVANCED SOLID TUMORS ELDERLY-PATIENTS RISK ESTROGEN-RECEPTOR radiotherapy TAMOXIFEN RESISTANCE MAMMARY-CARCINOMA MODEL TAMOXIFEN POSTOPERATIVE RADIOTHERAPY COMPLETE RESPONSE prevention SINGLE-AGENT GEMCITABINE PEPTIDE PRIMARY PERITONEAL AROMATASE INHIBITOR LETROZOLE PHASE-II METALLOPROTEINASE INHIBITOR BMS-275291 clinical trials Urology & Nephrology PLUS CISPLATIN hormonal therapy PREVENTION TEXAPHYRIN 4-hydroxyandrostenedione non-small cell lung cancer chemotherapy-quality of life-targeted therapy neoplasm metastasis third-line SERM breast conserving surgery renal cell AROMATASE INHIBITORS HYPERTHERMIA SURGERY esophageal cancer SU11248 RECURRENCE MASTECTOMY CHEMOTHERAPY REGIMENS DOCETAXEL GEOGRAPHIC-VARIATION TRIAL PHASE-I CHEMOTHERAPY fulvestrant LOCAL THERAPY LYMPHOCYTES FIRST-LINE THERAPY NEOPLASM STAR RALOXIFENE INTERFERON-ALPHA CYP2D6 GENOTYPE DNA TOPOISOMERASE-I UPDATED FINDINGS VINDESINE PLUS CISPLATIN ANTI-TUMOUR AGENT POOLED ANALYSIS LONG-TERM ORAL VINORELBINE PLUS PREDNISONE END-POINTS COOPERATIVE-ONCOLOGY-GROUP radiation therapy repeat irradiation FIRST-LINE SUPPORTIVE CARE fourth-line therapy second-line therapy toxicity OUTCOMES prostate cancer 2-STAGE DESIGNS STAGE-I TUMOR 474 TAMOXIFEN ICI 46 Andrology SYSTEMIC THERAPY SUPPORTIVE INHIBITOR HUMAN CARCINOEMBRYONIC ANTIGEN sunitinib GYNECOLOGIC-ONCOLOGY-GROUP antihormone resistance Motexafin gadolinium KNOWLEDGE ENDOMETRIAL CANCER FLUOROURACIL CONSERVING SURGERY raloxifene PROGRESSION-FREE SURVIVAL TYROSINE KINASE therapy angiogenesis neu PATIENTS PREFERENCES PREOPERATIVE RADIOTHERAPY FOLLOW-UP SINGLE-AGENT VINORELBINE CONSERVING aromatase inhibitors LEUKEMIA GROUP-B QUALITY-OF-LIFE CONSERVING THERAPY ADVANCED ESOPHAGOGASTRIC CANCER ADVANCED BREAST-CANCER irinotecan GASTROESOPHAGEAL ADENOCARCINOMA 5-FLUOROURACIL CARCINOMA-IN-SITU ER-ALPHA EXPRESSION Neurologic progression 20-YEAR FOLLOW-UP AROMATASE INHIBITOR DOSE-ESCALATION carcinoma rectal cancer GENE-TRANSCRIPTION GROWTH-FACTOR RECEPTOR PROGNOSTIC-FACTORS ADVANCED GASTRIC-CANCER docetaxel HER2 VINORELBINE PLUS CISPLATIN LETROZOLE PREMENOPAUSAL WOMEN appropriateness criteria conflict
Last updated on Wednesday, February 05, 2020